Avexitide: The GLP-1 Blocker Racing to a Phase 3 Readout — Turning the Obesity Drug Class Upside Down (August 4, 2026)
Table of Contents
The drug that blocks the receptor everyone else activates
The GLP-1 receptor is the most valuable target in medicine right now. Semaglutide, tirzepatide, and the new oral pill orforglipron all work by switching it ON — boosting insulin, slowing the stomach, and dialing down appetite. Avexitide does the exact opposite: it is a GLP-1 receptor ANTAGONIST that switches the receptor OFF. That sounds backwards until you meet the patients it is designed for — people whose bodies release far too much insulin at the wrong moment, sending their blood sugar crashing. For them, blunting GLP-1 signaling is not a side effect to avoid; it is the entire therapeutic goal.
What avexitide actually is
Chemically, avexitide is exendin (9-39): a synthetic 31-amino-acid peptide that is a fragment of exendin-4, the same lizard-derived peptide that inspired the diabetes drug exenatide. Clip off the front of exendin-4 and what remains binds the GLP-1 receptor tightly but does not activate it — a potent, selective competitive antagonist. Given once daily by injection, avexitide occupies the receptor and prevents the exaggerated, glucose-independent insulin surges that drive hypoglycemia.
The target: post-bariatric hypoglycemia
Avexitide's lead indication is post-bariatric hypoglycemia (PBH), a debilitating complication of Roux-en-Y gastric bypass. After surgery, food rushes into the intestine and triggers an oversized GLP-1 and insulin response; an hour or two after eating, blood sugar plummets, causing shakiness, confusion, and even loss of consciousness. There is currently no FDA-approved treatment. In a Phase 2b trial, avexitide 90 mg once daily cut the composite rate of Level 2 and Level 3 hypoglycemic events by 64% (least-squares mean) — a large, mechanistically clean effect that set up the pivotal program.
LUCIDITY: the Phase 3 that matters
The pivotal Phase 3 LUCIDITY trial (NCT06747693) enrolled 78 adults with PBH after gastric bypass into a 16-week, randomized, double-blind, placebo-controlled study. Its primary endpoint — agreed in advance with the FDA — is the reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16. Amylyx completed enrollment in March 2026 and expects topline data in the third quarter of 2026. If the readout is positive, the company has pointed to a potential U.S. commercial launch in 2027. Avexitide already holds FDA Breakthrough Therapy Designation in PBH plus Orphan Drug Designation.
A second front: congenital hyperinsulinism
The same logic applies to congenital hyperinsulinism (HI), an ultra-rare, life-threatening pediatric disorder in which the pancreas secretes too much insulin, causing persistent hypoglycemia that can produce irreversible brain damage in up to half of affected children. Exendin (9-39) has reduced hyperinsulinemic hypoglycemia across three completed Phase 2 studies in neonates, children, and adolescents, and the compound carries a separate Breakthrough Therapy Designation in congenital HI (originally granted to Eiger in 2021). Amylyx has said it is working with the HI community on a development path.
How avexitide reached Amylyx
Avexitide was developed by Eiger BioPharmaceuticals, which ran it through five clinical trials. When Eiger filed for Chapter 11 bankruptcy in April 2024, Amylyx — fresh off discontinuing its ALS drug — acquired the Phase 3-ready asset for roughly $35.1 million in July 2024, using it to pivot the company squarely into metabolic disease. It was an unusual bet: while the rest of the industry chased GLP-1 agonists for obesity, Amylyx bought the antagonist.
Why it matters
Avexitide is the clearest proof yet that the GLP-1 axis can be tuned in both directions. The agonists made GLP-1 famous by activating the receptor for weight loss and diabetes; avexitide shows that blocking the very same receptor can rescue patients on the opposite end of the spectrum, whose problem is too much insulin rather than too little. For the tens of thousands living with post-bariatric hypoglycemia and the families facing congenital hyperinsulinism, a first-in-class, mechanism-matched therapy with an imminent Phase 3 readout is a genuinely new option.
The bottom line
Avexitide (exendin 9-39) is an investigational, once-daily injectable GLP-1 receptor antagonist — the mirror image of semaglutide and tirzepatide — being developed by Amylyx for hyperinsulinemic hypoglycemia. Its pivotal Phase 3 LUCIDITY trial in post-bariatric hypoglycemia is fully enrolled, with topline data expected in Q3 2026. It is not approved anywhere, it is not a weight-loss drug, and it is not a supplement or research chemical; any 'avexitide' sold by a vendor is unverified.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Amylyx Pharmaceuticals — Completion of Enrollment in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia Source
- [2] Amylyx Pharmaceuticals — Acquisition of Phase 3-ready GLP-1 Receptor Antagonist Avexitide with FDA Breakthrough Therapy Designation (July 2024) Source
- [3] Amylyx Pharmaceuticals — First Quarter 2026 Financial Results Source
- [4] Exendin (9-39) Effects on Glucose and Insulin in Children With Congenital Hyperinsulinism — Diabetes Care Source
- [5] LUCIDITY — ClinicalTrials.gov NCT06747693 Source
Related Articles
Eli Lilly's Foundayo (orforglipron) becomes the first oral non-peptide GLP-1 approved for weight loss, CagriSema shows superiority over semaglutide alone in REIMAGINE-2, semaglutide enters Alzheimer's Phase 3 trials, tirzepatide reduces sleep apnea events, and the FDA peptide reclassification moves forward.
Setmelanotide (Imcivree): The MC4R Peptide That Treats Obesity the GLP-1 Drugs Can't (June 26, 2026)
Setmelanotide (Imcivree) is a cyclic octapeptide that activates the brain's MC4R appetite switch directly — treating rare genetic and post-tumor hypothalamic obesity that GLP-1 drugs were never designed for. In March 2026 the FDA expanded it to acquired hypothalamic obesity, making it the first and only approved therapy for that condition.
KAI-7535: Another Oral GLP-1 Pill Clears Phase 3 — With a Clean Liver-Safety Readout (August 2, 2026)
The oral GLP-1 pill race just added another late-stage entrant. Hengrui's HRS-7535 — developed outside China by Kailera as KAI-7535 — posted up to 10.9% weight loss at Week 44 in a Chinese Phase 3 obesity trial and beat dapagliflozin on blood sugar in a diabetes trial, with no liver-safety signal. Here is what the data show and where it sits versus orforglipron and aleniglipron.